Industry News
EyeCool Therapeutics Reports Positive Pilot Study Results for ETX-4143 in Chronic Ocular Surface Pain (COSP)

EyeCool Therapeutics has announced encouraging results from a double-masked, randomized controlled p...

read more
EyeCool Therapeutics Reports Positive Pilot Study Results for ETX-4143 in Chronic Ocular Surface Pain (COSP)
May 12, 2025
Perfuse Therapeutics Reports Positive Phase 1/2a Results for PER-001 Intravitreal Implant in Glaucoma

Perfuse Therapeutics has announced promising 24-week results from its Phase 1/2a clinical trial eval...

read more
Perfuse Therapeutics Reports Positive Phase 1/2a Results for PER-001 Intravitreal Implant in Glaucoma
May 12, 2025
LumiThera’s LIGHTSITE Phase 3B Extension Trial Demonstrates Long-Term Vision Improvement in Dry AMD

LumiThera has announced promising results from its LIGHTSITE 3B extension trial, highlighting contin...

read more
LumiThera’s LIGHTSITE Phase 3B Extension Trial Demonstrates Long-Term Vision Improvement in Dry AMD
May 12, 2025
Topcon Healthcare Launches IDHea to Advance AI and Digital Health Innovation from Ocular Data

Topcon Healthcare has officially launched the Institute of Digital Health (IDHea), a next-generation...

read more
Topcon Healthcare Launches IDHea to Advance AI and Digital Health Innovation from Ocular Data
May 09, 2025
Alkeus Pharmaceuticals Presents Positive 24-Month Phase 2 Data for Gildeuretinol in GA at ARVO 2025

Alkeus Pharmaceuticals, Inc. presented additional 24-month results from its Phase 2 SAGA clinical tr...

read more
Alkeus Pharmaceuticals Presents Positive 24-Month Phase 2 Data for Gildeuretinol in GA at ARVO 2025
May 09, 2025
Aldeyra to Resubmit NDA for Reproxalap Following Positive Phase 3 Dry Eye Chamber Results

Aldeyra Therapeutics has announced that its investigational dry eye disease (DED) candidate, reproxa...

read more
Aldeyra to Resubmit NDA for Reproxalap Following Positive Phase 3 Dry Eye Chamber Results
May 08, 2025
Innovent Biologics Presents 1-Year Phase 2 Data on IBI302 for nAMD at ARVO 2025

Innovent Biologics has announced the latest 1-year results from its Phase 2 clinical trial evaluatin...

read more
Innovent Biologics Presents 1-Year Phase 2 Data on IBI302 for nAMD at ARVO 2025
May 08, 2025
Carl Zeiss Meditec AG Announces Leadership Change

Carl Zeiss Meditec AG has announced a forthcoming change in executive leadership. Dr. Markus Weber, ...

read more
Carl Zeiss Meditec AG Announces Leadership Change
May 08, 2025
Opus Genetics Presents 12-Month OPGx-LCA5 Gene Therapy Data at ARVO 2025

Opus Genetics has presented 12-month results from adult patients enrolled in the ongoing Phase 1/2 c...

read more
Opus Genetics Presents 12-Month OPGx-LCA5 Gene Therapy Data at ARVO 2025
May 07, 2025
UNITY Biotechnology Reports 36-Week Results from Phase 2b ASPIRE Trial of UBX1325 in DME

UNITY Biotechnology has announced the complete 36-week results from its Phase 2b ASPIRE clinical tri...

read more
UNITY Biotechnology Reports 36-Week Results from Phase 2b ASPIRE Trial of UBX1325 in DME
May 07, 2025
More